我们暂停阿西莫夫出版社。
We're Pausing Asimov Press

原始链接: https://www.asimov.press/p/pause

阿西莫夫出版社将于四月暂时停止运营,但现有文章将继续免费在线提供。该出版社于2023年6月成立,核心团队仅由尼科和赞德·巴尔维特两位编辑组成,订阅用户迅速从7000人增长到42000人,共发表了149篇文章,每月覆盖约50万读者。 该出版社以深入的科学写作而著称,涵盖从历史分析(《青霉素神话》)到未来推测等主题,甚至影响了临床试验和细胞器工程资助方面的政策讨论。阿西莫夫出版社还成功出版了两本选集,其中包括一本以传统油墨*和*DNA印刷的独特书籍。 此次暂停并非由于财务问题——在阿西莫夫、阿斯特拉研究所和Stripe的支持下——而是因为创始团队有了新的承诺。尼科强调了过程的价值——高质量科学写作所需深入的研究和协作——并表示有信心未来的领导层将继续阿西莫夫出版社探索科学历史和未来的承诺。

## 阿西莫夫出版社暂停出版 阿西莫夫出版社,一家以通俗科学写作见长的出版机构,宣布暂停运营。这一消息在Hacker News上引发讨论,许多人质疑它与已故科幻作家艾萨克·阿西莫夫的关系——它在编辑上是独立的,并且是基因工程公司的一部分。 评论者们争论该公告是否充分解释了阿西莫夫出版社*是什么*,一些人认为它对于不熟悉该出版物的读者来说结构不佳。另一些人则为该帖子辩护,认为它是针对现有粉丝的。一个反复出现的主题是使用名人名字为公司命名的伦理问题,以及在某人去世后多久才变得可以接受。 许多评论者分享了与阿西莫夫出版社的积极体验,赞扬其深入但易于理解的科学文章。该出版物依靠资助和其母公司支持,凸显了维持独立科学新闻报道的挑战。讨论还涉及了像《阿西莫夫科幻》和《Analog》这样的科学出版物的更广泛困境。
相关文章

原文

Asimov Press is going on hiatus. While a few more articles will appear over the next month — and our stunning hardcover book, Making the Modern Laboratory, will come out this summer — operations will pause in April. All articles will remain freely accessible online.

As we prepare to pause, I want to celebrate what we’ve accomplished. In June 2023, Asimov Press was just a vague idea. (I remember posting the announcement from my phone in the Amsterdam metro, feeling a deep sense of fear about what we were starting.) A few months later, I brought on Xander Balwit. The two of us were its only editors and only full-time staff. We launched with about 7,000 subscribers, ported over from my personal blog, Codon. Our first article appeared in January 2024.

While I had attended journalism school and thought I knew about publishing, I soon discovered that literally everything — from managing people, to recruiting and paying writers, to fact-checking stories, printing books, and much else — doesn’t play out as it’s taught in school. By trial and error, Xander and I had to learn how to develop an eye for writers with exceptional promise, separate good pitches from vague ones, figure out which parts of a draft were most compelling, and make sure stories were told deeply enough to satisfy scientists, while remaining accessible to all “ambitious” readers.

Devon Balwit served as Copy Editor, helping us to convey these complex ideas in readable prose. In 2025, we hired Ella Watkins-Dulaney as our Art Director, and she promptly improved our header images and style. In the last several months, she has stepped into other roles as well, helping fact-check and compile the latest book. Ulkar Aghayeva composed and recorded the music for our podcasts, and also wrote several excellent articles for our pages. We’re also immensely grateful to the dozens of fact-checkers, artists, proofreaders, and writers who have contributed to maintaining a high bar of excellence at Asimov Press.

We’ve come a long way since our inception. Today, we have about 42,000 subscribers between Substack and our website. The press has published 149 original articles, reaching about half a million readers each month.

These articles have ranged from short to long, and from technical reports to history to speculative fiction. Some personal favorites have been The Penicillin Myth, about how Alexander Fleming’s discovery story may have been partly fabricated, How Nature Became a ‘Prestige’ Journal, What Makes an Experiment Beautiful?, and The Making of a Gene Circuit.

While many of our pieces were widely discussed, a handful made an even more tangible impact in the world. Our two recent essays on clinical trials — Clinic-in-the-Loop and AI Won’t Automatically Accelerate Clinical Trials — have been widely discussed in policy circles, as has the essay on China’s Clinical Trial Boom. The essay Mitochondria Are Alive became a bit of a rallying cry for funders considering new tools to engineer these organelles. An essay on artemisinin’s discovery was cited in discussions that led to the Research Revival Fund, a new nonprofit seeking to restore “neglected, illegible, or prematurely dismissed research.”

The Press has published and sold out of two anthologies. When we first tried our hand at printing books, we assumed we would lose a lot of money as printing is expensive, and around 96 percent of all books sell fewer than 1,000 copies. But in both cases, we sold thousands of copies, recouped our costs, and donated the profit to charities. I’m especially proud of our second book, the first commercially available book published in both print and DNA. It was mentioned in The New Yorker and featured in WIRED magazine. Thanks again to the companies that made it possible.

Our decision to pause is not related to funding. Asimov has supported us for the last two years, and we’ve received generous grants from Astera Institute and Stripe. But new projects have called away Xander and I, making it a good time to recalibrate.

For me, the greatest part of writing and editing is drawing closer to ideas and the people who generate them. Essays are a forcing function toward both. Great writers often find an exciting idea and decide to pursue it, only to confront a gap that nothing on the internet can fill — a question too deep or too specific to answer alone. And so the work begins: emailing and calling people, visiting where they work, hosting dinners, and sometimes flying around the world to understand it. The search for great ideas, and a deep understanding of them, is why I’ll keep writing, and helping others do so, for the rest of my life.

When Asimov Press reemerges, I know that those who lead it will be just as curious about the history and future of science as we have been. Thank you for taking this journey with us.

Until next time,

— Niko

联系我们 contact @ memedata.com